Leland Gershell
Stock Analyst at Oppenheimer
(4.25)
# 375
Out of 4,873 analysts
133
Total ratings
38.52%
Success rate
23.78%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAPR Capricor Therapeutics | Maintains: Outperform | $43 → $22 | $9.24 | +138.22% | 5 | Jun 23, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $215 → $224 | $178.40 | +25.56% | 11 | Jun 13, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | $10 | $1.28 | +681.25% | 1 | Jun 6, 2025 | |
| URGN UroGen Pharma | Maintains: Outperform | $36 → $10 | $13.69 | -26.95% | 10 | Jun 3, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $6 → $7 | $4.60 | +52.17% | 2 | May 9, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $704 → $708 | $568.51 | +24.54% | 7 | May 9, 2025 | |
| QNCX Quince Therapeutics | Initiates: Outperform | $10 | $1.39 | +619.42% | 1 | Mar 24, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Outperform | $12 → $20 | $5.61 | +256.51% | 3 | Mar 11, 2025 | |
| BMRN BioMarin Pharmaceutical | Upgrades: Outperform | $98 | $54.34 | +80.36% | 3 | Feb 24, 2025 | |
| RYTM Rhythm Pharmaceuticals | Initiates: Outperform | $76 | $62.10 | +22.39% | 1 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $52 | $17.82 | +191.81% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $135 → $147 | $117.60 | +25.00% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.63 | +692.39% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.72 | - | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $73 | $83.81 | -12.90% | 8 | Oct 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $15.82 | +235.02% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $43.33 | - | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $3.02 | +895.02% | 2 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $1.76 | +583.76% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $25 | $0.09 | +27,708.68% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 → $28 | $14.79 | +89.38% | 5 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $3.09 | +710.37% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 → $73 | $30.82 | +136.86% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $1.61 | +1,146.11% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $22.07 | +31.40% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $4.88 | +617.21% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.67 | +1,392.54% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $1.64 | +1,119.51% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $322.73 | - | 7 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.78 | +630.30% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $2.34 | +5,039.19% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.09 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $360,000 | $0.40 | +89,263,475.50% | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $17.23 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.31 | +3,716.79% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $16.35 | - | 5 | Mar 31, 2020 |
Capricor Therapeutics
Jun 23, 2025
Maintains: Outperform
Price Target: $43 → $22
Current: $9.24
Upside: +138.22%
Ascendis Pharma
Jun 13, 2025
Maintains: Outperform
Price Target: $215 → $224
Current: $178.40
Upside: +25.56%
Climb Bio
Jun 6, 2025
Initiates: Outperform
Price Target: $10
Current: $1.28
Upside: +681.25%
UroGen Pharma
Jun 3, 2025
Maintains: Outperform
Price Target: $36 → $10
Current: $13.69
Upside: -26.95%
Xeris Biopharma Holdings
May 9, 2025
Maintains: Outperform
Price Target: $6 → $7
Current: $4.60
Upside: +52.17%
argenx SE
May 9, 2025
Maintains: Outperform
Price Target: $704 → $708
Current: $568.51
Upside: +24.54%
Quince Therapeutics
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $1.39
Upside: +619.42%
Trevi Therapeutics
Mar 11, 2025
Maintains: Outperform
Price Target: $12 → $20
Current: $5.61
Upside: +256.51%
BioMarin Pharmaceutical
Feb 24, 2025
Upgrades: Outperform
Price Target: $98
Current: $54.34
Upside: +80.36%
Rhythm Pharmaceuticals
Dec 20, 2024
Initiates: Outperform
Price Target: $76
Current: $62.10
Upside: +22.39%
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $17.82
Upside: +191.81%
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $117.60
Upside: +25.00%
Nov 5, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.63
Upside: +692.39%
Nov 4, 2024
Downgrades: Perform
Price Target: n/a
Current: $1.72
Upside: -
Oct 28, 2024
Maintains: Outperform
Price Target: $65 → $73
Current: $83.81
Upside: -12.90%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $15.82
Upside: +235.02%
Oct 3, 2024
Initiates: Perform
Price Target: n/a
Current: $43.33
Upside: -
Sep 24, 2024
Reiterates: Outperform
Price Target: $30
Current: $3.02
Upside: +895.02%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $1.76
Upside: +583.76%
Sep 3, 2024
Maintains: Outperform
Price Target: $150 → $25
Current: $0.09
Upside: +27,708.68%
Aug 12, 2024
Reiterates: Outperform
Price Target: $31 → $28
Current: $14.79
Upside: +89.38%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $3.09
Upside: +710.37%
Aug 9, 2024
Reiterates: Outperform
Price Target: $74 → $73
Current: $30.82
Upside: +136.86%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $1.61
Upside: +1,146.11%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $22.07
Upside: +31.40%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $4.88
Upside: +617.21%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.67
Upside: +1,392.54%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $1.64
Upside: +1,119.51%
Oct 11, 2023
Downgrades: Perform
Price Target: n/a
Current: $322.73
Upside: -
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.78
Upside: +630.30%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $2.34
Upside: +5,039.19%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $4.09
Upside: -
Jun 4, 2021
Initiates: Outperform
Price Target: $360,000
Current: $0.40
Upside: +89,263,475.50%
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $17.23
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $1.31
Upside: +3,716.79%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $16.35
Upside: -